Intracoronary Compared to Intravenous Abciximab in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention Reduces Mortality, Target Vessel Revascularization and Reinfarction after 1 Year

Objectives: Administration of the glycoprotein IIb/IIIa inhibitor abciximab to patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) improves outcome. Data have suggested that an intracoronary (IC) bolus might be superior to the standard intravenous (IV) administration. We have previously reported reduced short-term mortality and need for target vessel revascularization (TVR) with the IC route. We now present long-term data from our randomized trial on IC versus IV abciximab in pPCI-treated STEMI patients. Methods: A total of 355 pPCI-treated STEMI patients were randomized to either IC or IV bolus abciximab followed by a 12hour IV infusion. Patients were followed for 1 year to observe mortality, TVR or myocardial infarction (MI) and the combination of these. Results: The two treatment arms (IV, n = 170; IC, n = 185) were similar with regard to baseline characterisReceived: June 28, 2011 Accepted after revision: August 23, 2011 Published online: November 23, 2011 Allan Zeeberg Iversen, MD Department of Cardiology Gentofte University Hospital Niels Andersens Vej, 65, DK–2900 Hellerup (Denmark) Tel. +45 2489 2476, E-Mail allive01 @ geh.regionh.dk © 2011 S. Karger AG, Basel 0008–6312/11/1201–0043$38.00/0 Accessible online at: www.karger.com/crd D ow nl oa de d by : 54 .1 91 .4 0. 80 5 /2 /2 01 7 12 :4 6: 20 P M